NetraMark's Chief Innovation and Regulatory Officer Luca Pani, MD, on why broad enrollment can obscure treatment effects, what makes an AI-derived subgroup credible, and how Phase 2 should inform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results